Shots:
The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care.
Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo,…
Shots:
Integrating scintigraphy with therapeutics, radiopharmaceutical companies have emerged profoundly in the past few decades. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market
With the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026. This year,…

